Treatment Considerations for Patients with High-Risk NDMM
Barry Hammer, PA-C, defines high-risk multiple myeloma and explains the treatment adjustments needed for newly-diagnosed patients.
Video Player is loading.
EP: 1.Personalized Therapy Options Are on the Horizon in Multiple Myeloma
EP: 2.Treatment Approaches for Patients With Newly-Diagnosed Multiple Myeloma (NDMM)
EP: 3.Transplant Eligibility in Patients With NDMM
Now Viewing
EP: 4.Treatment Considerations for Patients with High-Risk NDMM
EP: 5.First-Line Treatment Options for Patients With Transplant-Ineligible NDMM
EP: 6.Data Updates on the Treatment of Transplant-Ineligible NDMM From the MAIA Trial
EP: 7.Selecting Between Doublet and Triplet Regimens for Patients With Transplant-Ineligible NDMM
EP: 8.Available Treatment Options for Patients with Relapsed Multiple Myeloma
EP: 9.Updates on Bispecific T-Cell Engager (BiTE) Antibodies in Relapsed Multiple Myeloma
EP: 10.Other Bispecific Antibodies Under Investigation for Treatment of Relapsed Multiple Myeloma
EP: 11.CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma
EP: 12.Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma
Recent Videos
Strategies for Monitoring and Managing T-DXd-Related Adverse Effects
The Evolving Role of T-DXd in HER2+ Metastatic Breast Cancer
Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
Current Treatment Approaches in HER2+ Metastatic Breast Cancer
Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit
Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum
Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management
Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS
Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies
Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
Related Content
